Compare NOAH & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOAH | ACRS |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Singapore | United States |
| Employees | 1778 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.6M | 529.9M |
| IPO Year | 2010 | 2015 |
| Metric | NOAH | ACRS |
|---|---|---|
| Price | $6.16 | $3.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $10.29 | $9.82 |
| AVG Volume (30 Days) | 332.1K | ★ 2.6M |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | ★ 10.65% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.24 | $2.46 |
| 52 Week High | $12.45 | $6.60 |
| Indicator | NOAH | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 30.35 | 39.18 |
| Support Level | N/A | $3.24 |
| Resistance Level | $8.98 | $4.60 |
| Average True Range (ATR) | 0.23 | 0.28 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 5.85 | 17.03 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.